This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Avalglucosidase alfa for treating Pompe disease

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Avalglucosidase alfa for treating Pompe disease

Pompe disease, also known as glycogen storage disorder type 2, is an autosomal recessive metabolic disorder caused by an enzymatic deficiency of acid alpha-glucosidase (GAA) in lysosomes

  • the disease was first described by J.C. Pompe, G. Bischoff, and W. Putschar-independently in the year 1932
  • enzyme replacement therapy (ERT) with alglucosidase alfa (Myozyme) received approval in Europe in 2006

NICE state:

  • avalglucosidase alfa (AVAL) is recommended, within its marketing authorisation, as an option for treating Pompe disease in babies, children, young people and adults, only if the company provides AVAL according to the commercial agreement

The NICE committee state:

  • "..Pompe disease either occurs at birth (infantile onset; IOPD), or after 12 months (late onset; LOPD). The only treatment for Pompe disease is enzyme replacement therapy (ERT) with alglucosidase alfa (ALGLU). AVAL is an alternative ERT that works in the same way. Limited evidence shows AVAL can enter cells more easily, so reducing glycogen levels more efficiently than ALGLU. But the clinical benefit is uncertain.."

Reference:


Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.